Healthcare Industry News: Stent-Graft
News Release - March 20, 2008
Cook Incorporated Wins Judgment In Patent Infringement Suit Filed By EdwardsCourt rules that Cook did not infringe Edwards' patents on devices to treat aneurysms
BLOOMINGTON, Ind.--(HSMN NewsFeed)--The United States District Court for the Northern District of California granted summary judgment in favor of Cook Incorporated rejecting claims filed by Edwards Lifesciences LLC alleging Cook had infringed on Edwards’ patents for endovascular devices to treat aneurysms, Cook officials announced today.
The case, C 03-03817 JSW, involved Edwards claiming patent infringement on four of Cook’s Zenith endovascular Stent-Grafts for use in treating abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs).
In its ruling, the Court rejected both of Edwards’ arguments, and determined “that no reasonable jury could conclude that Cook’s accused devices” literally infringed the Edwards patents, and “that Edwards cannot, as a matter of law, show that Cook’s accused devices infringe the patents-in-suit under the doctrine of equivalents. Cook, therefore, is entitled to judgment in its favor on this basis as well,” the Court wrote in its decision.
About Cook Medical
Cook Medical was one of the first companies to introduce interventional devices in the United States. Today, the company integrates device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Cook is a past winner of the prestigious Medical Device Manufacturer of the Year Award from Medical Device & Diagnostic Industry magazine. For more information, visit www.cookmedical.com.
Source: Cook Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.